Articles dans des revues avec comité de lecture (182)
34.
Lepida, A., Marot, A., Trepo, E., Degré, D., Moreno, C., & Deltenre, P. (2019). Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites. Alimentary pharmacology & therapeutics, 50(9), 978-987. doi:10.1111/apt.1550235.
Hees, S. V., Chi, H., Hansen, B., Bourgeois, S., Vlierberghe, H. V., Serste, T., Francque, S., Wong, D., Sprengers, D., Moreno, C., Nevens, F., Janssen, H. H., & Vanwolleghem, T. (2019). Caucasian Ethnicity, but Not Treatment Cessation is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion. Viruses, 11(8). doi:10.3390/v1108068736.
Opstaele, L., Bielen, R., Bourgeois, S., Moreno, C., Nevens, F., Robaeys, G., & Van Vlierberghe, H. (2019). Who to screen for hepatitis c? A cost-effectiveness study in Belgium of comprehensive hepatitis c screening in four target groups. Acta Gastro-Enterologica Belgica (English ed.), 82(3), 379-387.37.
Barrail-Tran, A., Goldwirt, L., Gelé, T., Laforest, C., Lavenu, A., Danjou, H., Radenne, S., Leroy, V., Houssel-Debry, P., Duvoux, C., Kamar, N., De Ledinghen, V., Canva, V., Conti, F., Durand, F., D’Alteroche, L., Botta-Fridlund, D., Moreno, C., Cagnot, C., Samuel, D., Fougerou-Leurent, C., Pageaux, G.-P., Duclos-Vallée, J.-C., Taburet, A. M., & Coilly, A. (2019). Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. European Journal of Clinical Pharmacology. doi:10.1007/s00228-019-02725-x38.
Zeuzem, S., Bourgeois, S., Greenbloom, S., Buti, M., Aghemo, A., Lampertico, P., Janczewska, E., Lim, S. G., Moreno, C., Buggisch, P., Tam, E., Corbett, C., Willems, W., Vijgen, L., Fevery, B., Ouwerkerk-Mahadevan, S., Ackaert, O., Beumont, M., Kalmeijer, R., Sinha, R., & Biermer, M. (2019). JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-Infected Patients Without Cirrhosis: OMEGA-1. Hepatology. doi:10.1002/hep.3052739.
Deltenre, P., Trepo, E., Fujiwara, N., Goossens, N., Marot, A., Dubois, M., Spahr, L., Henrion, J., Moreno, C., & Hoshida, Y. (2019). Gene signature-MELD score and alcohol relapse determine long-term prognosis of patients with severe alcoholic hepatitis. Liver international. doi:10.1111/liv.1426540.
Van Hees, S., Chi, H., Hansen, B., Bourgeois, S., Van Vlierberghe, H., Serste, T., Francque, S., Wong, D., Sprengers, D., Moreno, C., Nevens, F., Janssen, H. H., & Vanwolleghem, T. (2019). Sustained off-treatment viral control is associated with high hepatitis B surface antigen seroclearance rates in Caucasian patients with nucleos(t)ide analogue–induced HBeAg seroconversion. Journal of viral hepatitis. doi:10.1111/jvh.1308441.
Avila, M., Dufour, J. F., Gerbes, A. L., Zoulim, F., Bataller, R., Burra, P., Cortez-Pinto, H., Gao, B., Gilmore, I., Mathurin, P., Moreno, C., Poznyak, V., Schnabl, B., Szabo, G., Thiele, M., & Thursz, M. M. (2019). Recent advances in alcohol-related liver disease (ALD): Summary of a Gut round table meeting. Gut. doi:10.1136/gutjnl-2019-31972042.
Asselah, T., Alami, N. N., Moreno, C., Pol, S., Karatapanis, S., Gschwantler, M., Horsmans, Y., Elefsiniotis, I., Larrey, D., Ferrari, C., Rizzetto, M., Orlandini, A., Calleja, J. L. U. J., Bruno, S., Schnell, G., Qaqish, R. R., Redman, R., Pilot-Matias, T., Kopecky-Bromberg, S., Yu, Y., & Mobashery, N. (2019). Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II). Health Science Reports, 2(3), e92. doi:10.1002/hsr2.9243.
Hedskog, C., Parhy, B., Chang, S., Zeuzem, S., Moreno, C., Shafran, S. S., Borgia, S. S., Asselah, T., Alric, L., Abergel, A., Chen, J. J., Collier, J., Kapoor, D., Hyland, R. R., Simmonds, P., Mo, H., & Svarovskaia, E. (2019). Identification of 19 novel hepatitis C virus subtypes-further expanding HCV classification. Open Forum Infectious Diseases, 6(3), ofz076. doi:10.1093/ofid/ofz076